Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2022)

Historic Cash from Financing Activities for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $147000.0.

  • Atea Pharmaceuticals' Cash from Financing Activities fell 8150.94% to $147000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $370000.0, marking a year-over-year decrease of 7474.4%. This contributed to the annual value of $267000.0 for FY2024, which is 389.11% up from last year.
  • Atea Pharmaceuticals' Cash from Financing Activities amounted to $147000.0 in Q3 2022, which was down 8150.94% from $223000.0 recorded in Q1 2022.
  • In the past 5 years, Atea Pharmaceuticals' Cash from Financing Activities ranged from a high of $426.2 million in Q4 2020 and a low of -$913000.0 during Q3 2020
  • In the last 3 years, Atea Pharmaceuticals' Cash from Financing Activities had a median value of $185000.0 in 2022 and averaged $53.4 million.
  • Data for Atea Pharmaceuticals' Cash from Financing Activities shows a peak YoY increase of 795000.0% (in 2021) and a maximum YoY decrease of 9996.67% (in 2021) over the last 5 years.
  • Atea Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $426.2 million in 2020, then tumbled by 99.97% to $142000.0 in 2021, then grew by 3.52% to $147000.0 in 2022.
  • Its Cash from Financing Activities was $147000.0 in Q3 2022, compared to $223000.0 in Q1 2022 and $142000.0 in Q4 2021.